(Q34667216)

3 August 2017

1 reference

title

Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline (English)

1 reference

3 August 2017

0 references

1 reference

1

Moussa B H Youdim

1 reference

3 August 2017

Marta Weinstock

2

1 reference

3 August 2017

publication date

1 April 2002

1 reference

Mechanisms of Ageing and Development

3 August 2017

published in

1 reference

3 August 2017

volume

123

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

1081-1086

1 reference

Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Rivastigmine for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022.

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

The future of neuroprotection

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

The Pivotal Role of Iron in NF-kappaB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0047-6374%2801%2900391-8

7 January 2021

10.1016/S0047-6374(01)00391-8

Identifiers

DOI

1 reference

3 August 2017

1 reference